The only likely catalyst for a substantial rerate of
the share price this year and beyond is an
outstanding 008 result, given present market
conditions, which are unlikely to improve for
some time. As you say GG, the dilution will be
pretty ugly. Does anyone have any idea just how
much money will be needed to complete trials
over next 3-4 years. At least the value of the
present MC I would think.
Compare the resources Novartis has to throw
at LNA043. Lets all hope for a partnership on
favourable terms for PAR very soon.
All IMO.
research reports and media, page-2753
-
- There are more pages in this discussion • 1,478 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.8¢ |
Change
0.008(2.50%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.5¢ | 29.5¢ | $137.3K | 452.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 22304 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 2234 | 6 |
View Market Depth
| Last trade - 15.54pm 17/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |